Question: is this a 2) strong advice, 1) weak advice 0) no advice?

In our trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter  (0.78 mmol per liter) and reduced the risk of cardiovascular events.
user
This is no advice
assistant